Cleveland BioLabs highlights biomarker response in radiation drug study; c-Met may be a biomarker for metastatic hepatocellular;

> Cleveland BioLabs says that its radiation treatment therapy has undergone a second successful human safety study, with the data demonstrating "a difference in biomarker response proportional to the dose applied as single intramuscular injections, meeting the primary goal of the trial." Report

> Targeting c-Met may be a promising personalized treatment method for approximately 45 percent of patients with hepatocellular carcinoma who have c-Met-positive tumors, according to study results presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development. Proteomics release

> Sirius Genomics has inked its second agreement with the National Research Council of Canada Industrial Research Assistance Program on the discovery of genomic biomarkers that can be used to predict patient response to therapeutics used in critical care medicine. Sirius release

> Thermo Fisher Scientific and Proteome Sciences agreed to collaborate on products for protein biomarker research. Thermo Fisher/Proteome release

> New research has found that reduced levels of brain-derived neurotrophic factor-a protein in the brain that encourages growth of neurons-may be a trait marker for individuals with psychogenic non-epileptic seizures. Release

> Two UK companies have been awarded joint funding for a research project that could see significant advances in the quest to aid detection and eradication of Tuberculosis across the world. NPL/Orla release